Last reviewed · How we verify

TTS-fentanyl

Janssen-Cilag Ltd.,Thailand · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

TTS-fentanyl is a Small molecule drug developed by Janssen-Cilag Ltd.,Thailand. It is currently FDA-approved. Also known as: Durogesic.

TTS-fentanyl is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist drug. It is used to treat various conditions, including hip fractures, chronic pain, low back pain, pain, and cancer, and is administered via a transdermal system.

At a glance

Generic nameTTS-fentanyl
Also known asDurogesic
SponsorJanssen-Cilag Ltd.,Thailand
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TTS-fentanyl

What is TTS-fentanyl?

TTS-fentanyl is a Small molecule drug developed by Janssen-Cilag Ltd.,Thailand.

Who makes TTS-fentanyl?

TTS-fentanyl is developed and marketed by Janssen-Cilag Ltd.,Thailand (see full Janssen-Cilag Ltd.,Thailand pipeline at /company/janssen-cilag-ltd-thailand).

Is TTS-fentanyl also known as anything else?

TTS-fentanyl is also known as Durogesic.

What development phase is TTS-fentanyl in?

TTS-fentanyl is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing